This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.
At the conclusion of this course, participants will be able to:
• Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
• Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice
• Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
• Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT
This course is intended for practicing radiologists, nuclear medicine physicians and radiologic nurses, physician assistants, technologists, residents, fellows and others who are interested in the clinical applications of PET and PET/CT.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Postgraduate Institute for Medicine and CME Science. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates these live activities for
16.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Technologists: This course is pending approval for up to 16 ARRT Category A CE credits for those technologists attending the entire course.